Kinney Horn Sells 90,616 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Kinney Horn sold 90,616 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the transaction, the insider directly owned 50,366 shares of the company’s stock, valued at approximately $1,263,682.94. The trade was a 64.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kinney Horn also recently made the following trade(s):

• On Tuesday, July 7th, Kinney Horn sold 1,092 shares of Immunome stock. The shares were sold at an average price of $25.00, for a total value of $27,300.00.

Immunome Price Performance

NASDAQ:IMNM opened at $25.03 on Friday. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of -10.52 and a beta of 2.08. Immunome, Inc. has a 1 year low of $8.66 and a 1 year high of $27.65. The business has a 50 day simple moving average of $21.49 and a 200-day simple moving average of $22.16.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IMNM. HC Wainwright reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Immunome in a research note on Tuesday, July 21st. Barclays began coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target on the stock. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, Leerink Partners decreased their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.18.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently bought and sold shares of the business. Citizens Financial Group Inc. RI purchased a new stake in Immunome in the second quarter worth $424,000. BlackRock Inc. purchased a new stake in shares of Immunome during the second quarter valued at $186,588,000. Deutsche Bank AG bought a new position in shares of Immunome in the second quarter worth about $2,365,000. Bank of New York Mellon Corp bought a new position in shares of Immunome in the second quarter worth about $6,333,000. Finally, State of Wyoming bought a new position in shares of Immunome in the second quarter worth about $109,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.